NONMEM Users Network Archive

Hosted by Cognigen

RE: Pharmacoeconomic simulations

From: Jon Monteleone <jmonteleone>
Date: Thu, 30 Apr 2009 00:07:58 -0400



Pharmacoeconomic means different things to different people, and the
following references should cover a useful spectrum



Poland B, Wada R. Combining drug-disease and economic modelling to
inform drug development decisions Drug Discovery Today. November


Korsan B, Dykstra K, Pullman W. Transparent Trade-Offs: A Clinical
Utility Index (CUI) Openly Evaluates a Product's Attributes - and Chance
of Success Pharmaceutical Executive. March 2005.


Poland B, Hodge F, Khan A, Clemen R, Dykstra K, Krishna R. The Clinical
Utility Index as a Practical Multiattribute Approach to Drug Development
Decisions (Accepted 2009)


Dykstra K, Hodge F, Carrothers TJ, Korsan B. Linking Modeling &
Simulation, Decision Analysis, and the Technology of Drug Formulation
American Conference on Pharmacometrics (ACoP); March 9-12, 2008; Tucson,


Hodge F, Using the Clinical Utility Index (CUI) to Inform Dose Selection
Decisions; Webinar February 2009;


Korsan B, Modeling and Decision Analysis to Support Formulation
Selection and Trial Sequencing, Webinar April 2006



Cheers -Jon



From: owner-nmusers
On Behalf Of jeffrey.a.wald
Sent: Thursday, April 23, 2009 4:39 PM
To: Bonate, Peter; nmusers
Subject: Re: [NMusers] Pharmacoeconomic simulations


A clinical utility index (CUI), as described recently by Ouellet et al.
Clinical Pharmacology & Therapeutics (2009); 85, 3, 277-282 as well as
by others elsewhere, is amenable to being used as a pharmacoeconomic
vehicle. Typically the CUI is derived in terms of patient benefit:risk,
but could easily be adapted to other tangible measures of value.



"Bonate, Peter" <Peter.Bonate
Sent by: owner-nmusers

23-Apr-2009 10:37







[NMusers] Pharmacoeconomic simulations




Is anyone aware of any papers or abstracts using computer-assisted trial
design that incorporates a pharmacoeconomic component to the simulation?
Or any pop pharmacokinetic-pharmacodynamic papers that include the same?


Pete bonate

Peter L. Bonate, PhD, FCP
Genzyme Corporation
Senior Director
Clinical Pharmacology and Pharmacokinetics
4545 Horizon Hill Blvd
San Antonio, TX 78229 USA
phone: 210-949-8662
fax: 210-949-8219
crackberry: 210-315-2713
"Beware of geeks bearing formulas". Written by Warren Buffet as part of
Berkshire Hathaway's 2009 Annual Report to Stockholders.

(image/gif attachment: image001.gif)

Received on Thu Apr 30 2009 - 00:07:58 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: